Farmaceutica Remedia (BSE:RMAH) Construction In Progress: lei0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:RMAH Farmaceutica Remedia SA BSE:RMAH
58 GF Score
Price lei0.87
GF Value lei0.79
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Farmaceutica Remedia Construction In Progress?

Farmaceutica Remedia BSE:RMAH +0.23% 58 Construction In Progress is lei0.0 Mil as of Mar. 2026. GuruFocus rates BSE:RMAH with a GF Score™ of 58/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 8 warning signs investors should review.

Farmaceutica Remedia's quarterly construction in progress increased from Sep. 2025 (lei0.0 Mil) to Dec. 2025 (lei1.4 Mil) but then declined from Dec. 2025 (lei1.4 Mil) to Mar. 2026 (lei0.0 Mil).

Farmaceutica Remedia's annual construction in progress increased from Dec. 2023 (lei0.7 Mil) to Dec. 2024 (lei1.1 Mil) and increased from Dec. 2024 (lei1.1 Mil) to Dec. 2025 (lei1.4 Mil).

Farmaceutica Remedia Construction In Progress Historical Data

* Premium members only.

The historical data trend for Farmaceutica Remedia's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia Construction In Progress Chart

Farmaceutica Remedia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.50 0.69 1.06 1.39

Farmaceutica Remedia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.39 0.00
BSE:RMAH
58GF Score
Farmaceutica Remedia SA BSE:RMAH
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of lei0.0 Mil mean?
Farmaceutica Remedia (BSE:RMAH) has a Construction In Progress of lei0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Construction In Progress too high?
Farmaceutica Remedia's current Construction In Progress is lei0.0 Mil. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Construction In Progress compare to MCK and CAH?
Farmaceutica Remedia's Construction In Progress of lei0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Distribution company?
A good Construction In Progress depends on the Medical Distribution industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Construction In Progress is lei0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Construction In Progress is lei0.0 Mil. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Construction In Progress is lei0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued. The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79. GuruFocus considers Farmaceutica Remedia to be Fairly Valued.

Key valuation signals for BSE:RMAH:

  • Construction In Progress: lei0.0 Mil
  • GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Farmaceutica Remedia Business Description

Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score

Get the complete analysis for BSE:RMAH

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.87
Price
lei0.79
GF Value